SecBot SecBot
Insider Cluster (2 insiders) ·Filed May 8, 2026

PTGX

Protagonist Therapeutics, Inc
NEUTRAL
Impact 5/10
Horizondays Processed6mo ago
Insider cluster: 2 insiders, $8.1M total
Actionable Insight • Neutral

The CEO's $7.5M sale at $100 is the largest insider sale in the trailing 30-day period ($11.9M total). While the company just reported transformative earnings, insider selling at these levels suggests limited near-term upside conviction. Monitor for additional insider sales or any lockup expiration disclosures. The stock's 89% analyst bullish rating may face headwinds if insiders continue to reduce positions.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$99.36
T+0 close · May 7, 2026 · via day close
Latest settled
+36.68%
T+60 · $135.81
Vs SPY
+31.85%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $99.36entry
  2. T+1 · 6mo ago +4.17%α +3.93% · $103.50
  3. T+5 · 6mo ago +6.23%α +4.77% · $105.55
  4. T+20 · 5mo ago −1.99%α −2.02% · $97.38
  5. T+60 · 3mo ago +36.68%α +31.85% · $135.81
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO Dinesh Patel and Director Bryan Giraudo sold a combined $11.7M in open-market shares within a week of PTGX reporting a massive Q1 2026 earnings beat (revenue $56.4M vs. $16.3M consensus, EPS $0.05 vs. -$0.65 consensus). The sales follow the FDA approval of ICOTYDE and a $200M rusfertide opt-out payment, but the CEO's $7.5M sale at ~$100/share, near all-time highs, raises questions about insider conviction at current valuation. At $11.7M total open-market sales, this represents ~0.17% of PTGX's $6.7B market cap, which is modest but notable given the CEO's participation and the post-earnings timing.

Key Financial Metrics

Direction
selling
Total Value
$11.7M
Insiders
2

Key Facts

  • CEO Dinesh Patel sold 75,000 shares at $100.12 for $7.51M on May 12, 2026
  • Director Bryan Giraudo sold 36,000 shares at $100.14 for $3.61M on May 7, 2026
  • Total open-market sales: $11.71M (0.17% of $6.7B market cap)
  • Sales occurred 2-7 days after Q1 2026 earnings beat (revenue $56.4M vs. $16.3M consensus)
  • CEO also exercised 150,000 options at $0 and $21.58 strike prices (non-cash events)
  • Stock is trading near all-time highs following ICOTYDE FDA approval and $200M milestone payment

Financial Impact

Insider sales of $11.71M represent 0.17% of market cap, modest but notable given CEO participation

insider ownershipmarket sentiment

Risk Factors

  • CEO selling near all-time highs may signal peak valuation sentiment
  • Further insider sales could pressure stock price
  • Post-earnings momentum may fade without additional catalysts

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-PTGX-1778628514248

Track record

11 reports on PTGX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +31.42% at T+60 after the May 5, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $132.04 Now $124.83 −5.46% settles Feb 4
  2. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $143.37 Now $124.83 −12.93% settles Feb 2
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $142.14 Now $124.83 −12.18% settles Jan 26
  4. Aug 10, 202614w ago 144 Bearish 5/10 Entry $148.29 to $143.37 Now $124.83 +15.82% ▲ +3.32% +2.83% vs SPY
  5. Jun 18, 202621w ago 8-K Neutral 3/10 Entry $115.03 to $143.40 Now $124.83 +8.52% ▲ +24.66% +22.92% vs SPY
  6. Jun 12, 202622w ago Institutional Cluster Mixed 5/10 Entry $109.78 to $145.94 Now $124.83 +13.71% ▲ +32.94% +29.67% vs SPY
  7. May 12, 202626w ago 144 Bearish 5/10 Entry $103.88 to $145.87 Now $124.83 −20.17% ▼ −40.42% −35.98% vs SPY
  8. May 8, 202627w ago Insider Cluster Neutral 4/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
  9. May 8, 202627w ago Insider Cluster Neutral 5/10 Viewing Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
  10. May 5, 202627w ago 8-K Bullish 7/10 Entry $103.97 to $136.64 Now $124.83 +20.06% ▲ +31.42% +29.36% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026